What one share of Jade Biosciences holds
We are a clinical-stage biopharmaceutical company developing novel biologic therapies for patients living with autoimmune diseases. Our goal is to improve meaningfully upon the existing treatment paradigm through the delivery of improved dosing and convenience, a comparable safety profile, and potentially increased clinical activity.
Jade Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.90 |
|---|---|
| Cash and investments | $1.69 |
| Debt | $0.00 |
| Book value | $6.92 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$40.31 | — | — | — | −$54.90 |
| 2021 | — | −$1.87 | $0.01 | −$2.24 | — | $7.06 |
| 2022 | — | −$2.10 | $0.01 | −$1.61 | — | $5.13 |
| 2023 | — | −$2.87 | $0.01 | −$2.16 | — | $3.94 |
| 2024 | — | −$2.44 | — | — | — | — |
| 2025 | — | −$3.19 | $0.01 | −$3.03 | — | $6.74 |
Common questions about Jade Biosciences
How much does one share of Jade Biosciences earn?
Over the last 12 months, Jade Biosciences lost $2.90 for each share.
Does Jade Biosciences pay a dividend?
Jade Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Jade Biosciences’s book value per share?
Jade Biosciences’s book value is $6.92 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Jade Biosciences have?
Each share of Jade Biosciences has $1.69 of cash and investments and $0.00 of debt, as of June 30, 2026.
Has Jade Biosciences bought back shares?
Jade Biosciences’s share count rose about 12846% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.